{"name":"Azurity Pharmaceuticals","slug":"azurity","ticker":"PRIVATE","exchange":"Private","domain":"azurity.com","description":"Azurity Pharmaceuticals is a specialty pharmaceutical company focused on pediatric and rare diseases. The company's top drugs include Azstarys, a treatment for attention deficit hyperactivity disorder (ADHD), and others. Azurity Pharmaceuticals operates in the US market and has a portfolio of marketed and pipeline products. The company's therapeutic focus is on pediatric and rare diseases.","hq":"Wilmington, MA","founded":0,"employees":"","ceo":"Richard Blackburn","sector":"Specialty Pharma / Pediatric","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"~$1.5B (PE valuation)","metrics":{"revenue":380000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Amphetamine Sulfate","genericName":"AMPHETAMINE SULFATE","slug":"amphetamine-sulfate","revenue":172000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1955-01-01","label":"Amphetamine Sulfate first approved","drug":"Amphetamine Sulfate","drugSlug":"amphetamine-sulfate","type":"approval","sentiment":"positive"},{"date":"1976-01-01","label":"Gleostine first approved","drug":"Gleostine","drugSlug":"lomustine","type":"approval","sentiment":"positive"},{"date":"1978-01-01","label":"Testosterone Cypionate first approved","drug":"Testosterone Cypionate","drugSlug":"depo-testosterone","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Vasotec first approved","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"approval","sentiment":"positive"},{"date":"1995-01-01","label":"Sular first approved","drug":"Sular","drugSlug":"nisoldipine","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Horizant first approved","drug":"Horizant","drugSlug":"gabapentin-enacarbil","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2036-03-25","label":"Vasotec patent expiry (Method of Use)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Method of Use)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Formulation)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Formulation)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Formulation)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Formulation)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Formulation)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Formulation)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-25","label":"Vasotec patent expiry (Formulation)","drug":"Vasotec","drugSlug":"enalapril-maleate","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Azstarys patent cliff ($123.4M at risk)","drug":"Azstarys","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":172000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Amphetamine Sulfate","genericName":"AMPHETAMINE SULFATE","slug":"amphetamine-sulfate","indication":"Attention deficit hyperactivity disorder","status":"marketed","revenue":172000000}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Testosterone Cypionate","genericName":"Testosterone Cypionate","slug":"depo-testosterone","indication":"Primary Hypogonadism","status":"marketed"},{"name":"Zonisamide Oral Product","genericName":"Zonisamide Oral Product","slug":"zonisamide-oral-product","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Sular","genericName":"NISOLDIPINE","slug":"nisoldipine","indication":"Hypertensive disorder","status":"marketed"},{"name":"Vasotec","genericName":"ENALAPRIL MALEATE","slug":"enalapril-maleate","indication":"Hypertension","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Gleostine","genericName":"LOMUSTINE","slug":"lomustine","indication":"Hodgkin's disease","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Horizant","genericName":"GABAPENTIN ENACARBIL","slug":"gabapentin-enacarbil","indication":"Postherpetic neuralgia","status":"marketed"}]}],"pipeline":[{"name":"Amphetamine Sulfate","genericName":"AMPHETAMINE SULFATE","slug":"amphetamine-sulfate","phase":"marketed","mechanism":"Sodium-dependent dopamine transporter","indications":["Attention deficit hyperactivity disorder","Narcolepsy","Obesity"],"catalyst":""},{"name":"Testosterone Cypionate","genericName":"Testosterone Cypionate","slug":"depo-testosterone","phase":"marketed","mechanism":"Androgen receptor","indications":["Primary Hypogonadism","Hypogonadotropic Hypogonadism"],"catalyst":""},{"name":"Gleostine","genericName":"LOMUSTINE","slug":"lomustine","phase":"marketed","mechanism":"Gleostine works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.","indications":["Hodgkin's disease","Neoplasm of brain"],"catalyst":""},{"name":"Horizant","genericName":"GABAPENTIN ENACARBIL","slug":"gabapentin-enacarbil","phase":"marketed","mechanism":"Horizant works by binding to the alpha-2/delta-1 subunit of voltage-dependent calcium channels, reducing the release of excitatory neurotransmitters and alleviating pain.","indications":["Postherpetic neuralgia","Restless legs"],"catalyst":""},{"name":"Sular","genericName":"NISOLDIPINE","slug":"nisoldipine","phase":"marketed","mechanism":"Sular works by blocking calcium channels in blood vessel walls, which relaxes the blood vessels and lowers blood pressure.","indications":["Hypertensive disorder"],"catalyst":""},{"name":"Vasotec","genericName":"ENALAPRIL MALEATE","slug":"enalapril-maleate","phase":"marketed","mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.","indications":["Hypertension","Symptomatic Congestive Heart Failure","Asymptomatic Left Ventricular Dysfunction"],"catalyst":""},{"name":"Zonisamide Oral Product","genericName":"Zonisamide Oral Product","slug":"zonisamide-oral-product","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Azurity Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Azurity Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $123.4 million and a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-16","type":"deal","headline":"Azurity Pharmaceuticals Announces Exclusive Distribution Agreement with a Leading Specialty Pharmacy","summary":"Azurity Pharmaceuticals announced an exclusive distribution agreement with a leading specialty pharmacy to expand the availability of its products.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPQkF4Q2oxTjdMTmI1VFBNWjVDWUsxTFRHYmRSb0dndkFNbE84VzBsc1M5aHFQMG5MQ1Z6N2VmMUVNbHNuZWFpMENRUTRwc0tQTmRsdUk0eDlNNmtic1VaTURBd2JPZ3hWZ001TEhKR2RhbklwZGwwdmYwajQ3MWNyZ0hqUnRSR3FEME9yd1JHcFFYU2FS?oc=5","date":"2026-03-25","type":"pipeline","source":"Secondaries Investor","summary":"QHP’s pharma single-asset delivers 10x for selling LPs - Secondaries Investor","headline":"QHP’s pharma single-asset delivers 10x for selling LPs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQTVhSdVhQLXFJTEVpSnducmJ4OG5OZnF3d0xITHFxZWFDVnoyYnhWT1hlRXAtdkItd2FuWTVmekEtR1NBVVgzQ1hWOG9OLTZBXzB6RTlGLUFucElGcjNkT1g5WnlCdlJPdkF2bzZaNEJoQlVYdTBtU0ZhZHNmdGNBbWVIa28wbk9tU1MyLUVqTGlnNGprUjJRTXk2dERQR3hFVE1SUFA2RXljajcweThhV3RXdVhLU2VSQU9xMURmRWhvRC1OS3hmQWhxbTR0ZEU?oc=5","date":"2026-03-18","type":"pipeline","source":"Business Wire","summary":"QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals - Business Wire","headline":"QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPdzlOOTZTTTRXVk42d1kzTjFoQkYzZXJOdVVGbHZUQjZYdEllanl6dElYTUV4RzdTV1pvQTJsUG9IenNOcGxQeXgyaHhtUXdRN3JOYnlhd254ZjNldGJQREtxaVB1M05tVTZuWmx1dFk2TDQ4cjVzUDRYMUV5NzlkdDB0V2NsenZRdTF1VWdvWkVpZGNIWmRuVm5UWFY?oc=5","date":"2025-06-06","type":"pipeline","source":"Secondaries Investor","summary":"QHP Capital runs single-asset CV process for pharma company – updated - Secondaries Investor","headline":"QHP Capital runs single-asset CV process for pharma company – updated","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQa1Z3U21kQ3hDemF3RUdSTmtSdGN2cGlSemM2aGxBNlA2WTl4aUVYZ01kVDM2VHVoZWotOHZXQWY4LWxSVWJiYVBKdmlRbkpZNFRjWUxMLUNQWnRLLTM1bkk4SUxqeTc0RG05ZVI2NTdXZDlYSW9sSjRQYnBST3dpUWZzMmtmekdQbktZUm9IZkhtdEU1ZEktQW0zS3RJYi1KWHFUd0ZhbFJmOWUtelN1UG5HVmdONnMt?oc=5","date":"2025-03-14","type":"pipeline","source":"PR Newswire","summary":"Azurity Pharmaceuticals Completes Acquisition of Covis Pharma - PR Newswire","headline":"Azurity Pharmaceuticals Completes Acquisition of Covis Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZHVINVdBUk1KSXg4ZUZidUM4MG1yT1lQaVFGVmdKUTF2X0lqYU9sSk4xU3FCdHg3Q05MVlRxWDlkTC1xbl92bGNkNVFBU2pKVTNvWm9MYk9iWEQ0ZlRMT1VQRi1GM2w1U3pEcFlla3BYcFo2RVl1MDU2UTdjNzN3ZkxNUTlXN2owekQtZzJyajFjZHk1SEVvN1dFRXlQZjJ3TjNweEtYMExXbE15SlZ3dkY3RG5Mb19JbjAyZ3VRVnM?oc=5","date":"2023-10-02","type":"pipeline","source":"White & Case LLP","summary":"White & Case advises Azurity Pharmaceuticals, Inc. on acquisition of Slayback Pharma, LLC - White & Case LLP","headline":"White & Case advises Azurity Pharmaceuticals, Inc. on acquisition of Slayback Pharma, LLC - White & Case LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPWGcxc0tYQ1pqUzBHc0E2dlg2OHgxVHFOYlhEUl8tMDUxdWhCQ0l0eE1tSkh6SlA1REpqX19BeFlaV3JNTTRnakhSbi1jM1l0SWRJSHMxUXppUnhvWTFVb2M5QTFPNW9mSkh2T1lBWWNBU29IeXhqcXIwYkZXNVQzWXl6X0c5TncwdFFDTlQ4eG0?oc=5","date":"2023-09-27","type":"deal","source":"citybiz","summary":"Azurity Pharmaceuticals Acquires Slayback Pharma - citybiz","headline":"Azurity Pharmaceuticals Acquires Slayback Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOeVVQYlFyQXdqXzRrZmsxU1FPLXFoRzV4RThtWVlXbmhfUVNzbFB4czZwc21mZU9oUk5RVjdkUlFnYVBoREFQT2J0WGVuZkxQdWR6YVM5WWExTDJDRkREbmc1NGxnUnk0YVE3Tm5MQUZvZ0duMVg1WHNBVnRKQVZRSmtfWUxzTGVkdkZMSGx1aXZGNVRlUlFLVVZndmlFWmxWN29PWFRKTU11Q2hMRERnN0ZrZXJjV09YSnc?oc=5","date":"2023-05-10","type":"pipeline","source":"ArentFox Schiff","summary":"ArentFox Schiff Uses Lanham Act to Secure $3.9 Million False Advertising Victory for Azurity Pharmaceuticals - ArentFox Schiff","headline":"ArentFox Schiff Uses Lanham Act to Secure $3.9 Million False Advertising Victory for Azurity Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPcF96UUFrYVNwNk0tUmplejR3NkFxOUUwTDdteldwZ1ZqYzRaaDR4WTFDM19aa0R4djRSX1hDTXZwUldPSFVWcXRFZ08wY3ZIcWtjblJRd0pjQlE5YVJESTdIWXZtUmRybDhUSUZjOUFVMnJTeTZyRUM3M2J3RUFGQ0JTVFVaMVlxNkxERmNIcUNHYUdvNWJ6UW9JcFlrS1pmLWVFVGtDOXpZMTFOMF8zNEFrbVlWYkhiRWFSUW16aUlrUGhjRUV3c2dGNV92X1FydE1KM3RYeTBOd0E?oc=5","date":"2021-11-08","type":"regulatory","source":"PR Newswire","summary":"AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF EPRONTIA™ (topiramate) oral solution - PR Newswire","headline":"AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF EPRONTIA™ (topiramate) oral solution","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQdDlCYzlBV3Z4NnVUTGtkaEZuLTc1ZGJ3V1pndjhNWVVoa2w2ZGNzcVZBeGxpUUN3NHpSekFqVS1Eb2F6MjZsakFLdWk5ai1IT3hGU0N3Qy1ibGpuMDFqTk9ySFZibmtRdllEOWFKdmRHUl9aSjROeGVGc0s3dkRHUjJaYnJJRlBvOHhPQzFrTlN2dGpTbE9Qbml4YS1nTmZEN21IVnh3UXM5UHJDb2t2TVBYdTA?oc=5","date":"2021-08-27","type":"deal","source":"Alternatives Watch","summary":"NovaQuest's Azurity Pharma acquires Arbor Pharma from KKR, others - Alternatives Watch","headline":"NovaQuest's Azurity Pharma acquires Arbor Pharma from KKR, others","sentiment":"neutral"}],"patents":[{"drugName":"Azstarys","drugSlug":"dexmethylphenidate-and-saccharin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":123400000},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"9808442","type":"Method of Use","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"10154987","type":"Method of Use","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"11040023","type":"Formulation","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"9669008","type":"Formulation","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"10772868","type":"Formulation","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"10786482","type":"Formulation","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"10039745","type":"Formulation","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"11173141","type":"Formulation","expiryDate":"2036-03-25","territory":"US","genericFilings":[]},{"drugName":"Vasotec","drugSlug":"enalapril-maleate","patentNumber":"11141405","type":"Formulation","expiryDate":"2036-03-25","territory":"US","genericFilings":[]}],"drugCount":7,"phaseCounts":{"marketed":7},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Tris Pharma","Sandoz","Teva Pharmaceuticals"],"therapeuticFocus":["Pediatric","Rare Diseases"],"financials":null,"yahoo":null}